ADC Pharmacokinetics and Clinical Pharmacology Summit

Kongressthemen
Antibody-drug conjugates (ADCs) have emerged as a rapidly evolving, highly promising class of oncology drugs, with 12 approvals and many more in development. Despite their success, the therapeutic window remains relatively narrow, posing challenges for finding an optimal dose.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/2465910-3?pid=4832

Speakers: Alison Betts, Global Head of DMPK and Modeling, Takeda, Andras Strassz, Chief Medical Officer, Heidelberg Pharma Research GmbH and more

https://go.evvnt.com/2465910-1?pid=4832

Frau Abigail Cox